Literature DB >> 26397756

Effects of daily delta-9-tetrahydrocannabinol treatment on heroin self-administration in rhesus monkeys.

David R Maguire1, Charles P France.   

Abstract

Opioid abuse remains a significant public health problem; together with the greater availability of marijuana in some regions there is an increasing likelihood that opioids and marijuana will be used together. Polydrug abuse is associated with increased toxicity and poorer treatment outcome; thus, a better understanding of the consequences of repeated coadministration of these drugs will facilitate the development of better prevention and treatment strategies. This study examined the effects of daily treatment with the cannabinoid receptor agonist delta-9-tetrahydrocannabinol (Δ-THC) and its discontinuation on self-administration of heroin in rhesus monkeys (n=4) lever-pressing under a fixed-ratio 30 schedule. Heroin self-administration (0.32-32 μg/kg/infusion, intravenously) generated an inverted U-shaped dose-effect curve. Administered acutely, Δ-THC (0.01-0.32 mg/kg, subcutaneously) dose dependently decreased responding for heroin and flattened the self-administration dose-effect curve. Daily treatment with Δ-THC (0.01-0.1 mg/kg/12 h, subcutaneously) either had no effect on or decreased responding for heroin. In addition, daily treatment did not significantly impact extinction of heroin self-administration or resumption of responding for heroin after extinction. Discontinuation of daily Δ-THC treatment did not systematically impact rates of heroin self-administration. These data suggest that repeated administration of a cannabinoid receptor agonist likely does not increase, and possibly decreases, the positive reinforcing effects of a mu opioid receptor agonist.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26397756      PMCID: PMC4779715          DOI: 10.1097/FBP.0000000000000192

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  38 in total

1.  The effect of persistence of cocaine use on 12-month outcomes for the treatment of heroin dependence.

Authors:  Anna Williamson; Shane Darke; Joanne Ross; Maree Teesson
Journal:  Drug Alcohol Depend       Date:  2005-09-09       Impact factor: 4.492

Review 2.  Major increases in opioid analgesic abuse in the United States: concerns and strategies.

Authors:  Wilson M Compton; Nora D Volkow
Journal:  Drug Alcohol Depend       Date:  2005-07-14       Impact factor: 4.492

3.  Behavioral effects in rhesus monkeys of repeated intravenous doses of 9-tetrahydrocannabinol.

Authors:  R T Harris; W Waters; D McLendon
Journal:  Psychopharmacologia       Date:  1972

4.  SR 141716A differentially attenuates the behavioral effects of delta9-THC in rhesus monkeys.

Authors:  L R McMahon; M R Amin; C P France
Journal:  Behav Pharmacol       Date:  2005-09       Impact factor: 2.293

Review 5.  Molecular and cellular basis of cannabinoid and opioid interactions.

Authors:  Daniela Viganò; Tiziana Rubino; Daniela Parolaro
Journal:  Pharmacol Biochem Behav       Date:  2005-06       Impact factor: 3.533

6.  Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats.

Authors:  Marcello Solinas; Leigh V Panlilio; Gianluigi Tanda; Alexandros Makriyannis; Stephanie A Matthews; Steven R Goldberg
Journal:  Neuropsychopharmacology       Date:  2005-11       Impact factor: 7.853

7.  Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers.

Authors:  Margaret Haney
Journal:  Neuropsychopharmacology       Date:  2006-11-08       Impact factor: 7.853

8.  An abstinence syndrome following chronic administration of delta-9-terahydrocannabinol in rhesus monkeys.

Authors:  A B Fredericks; N L Benowitz
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

9.  Interactions between Delta(9)-tetrahydrocannabinol and mu opioid receptor agonists in rhesus monkeys: discrimination and antinociception.

Authors:  Jun-Xu Li; Lance R McMahon; Lisa R Gerak; Ginger L Becker; Charles P France
Journal:  Psychopharmacology (Berl)       Date:  2008-05-10       Impact factor: 4.530

10.  Self administration of heroin and cocaine in morphine-dependent and morphine-withdrawn rhesus monkeys.

Authors:  Lisa R Gerak; Ruggero Galici; Charles P France
Journal:  Psychopharmacology (Berl)       Date:  2009-02-05       Impact factor: 4.530

View more
  11 in total

1.  Antinociceptive effects of mixtures of mu opioid receptor agonists and cannabinoid receptor agonists in rats: Impact of drug and fixed-dose ratio.

Authors:  David R Maguire; Charles P France
Journal:  Eur J Pharmacol       Date:  2017-11-26       Impact factor: 4.432

2.  Effects of morphine/CP55940 mixtures on an impulsive choice task in rhesus monkeys.

Authors:  Vanessa Minervini; Charles P France
Journal:  Behav Pharmacol       Date:  2018-02       Impact factor: 2.293

3.  Interactions between opioids and cannabinoids: Economic demand for opioid/cannabinoid mixtures.

Authors:  David R Maguire; Charles P France
Journal:  Drug Alcohol Depend       Date:  2020-05-12       Impact factor: 4.492

4.  Effects of the synthetic cannabinoid receptor agonist JWH-018 on abuse-related effects of opioids in rhesus monkeys.

Authors:  Lisa R Gerak; Peter F Weed; David R Maguire; Charles P France
Journal:  Drug Alcohol Depend       Date:  2019-06-29       Impact factor: 4.492

5.  Δ9-tetrahydrocannabinol attenuates oxycodone self-administration under extended access conditions.

Authors:  Jacques D Nguyen; Yanabel Grant; Kevin M Creehan; Candy S Hwang; Sophia A Vandewater; Kim D Janda; Maury Cole; Michael A Taffe
Journal:  Neuropharmacology       Date:  2019-04-11       Impact factor: 5.250

6.  Interactions between cannabinoid receptor agonists and mu opioid receptor agonists in rhesus monkeys discriminating fentanyl.

Authors:  David R Maguire; Charles P France
Journal:  Eur J Pharmacol       Date:  2016-05-13       Impact factor: 4.432

Review 7.  Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date.

Authors:  Reda M Chalhoub; Peter W Kalivas
Journal:  Drugs       Date:  2020-10       Impact factor: 9.546

8.  Reinforcing effects of opioid/cannabinoid mixtures in rhesus monkeys responding under a food/drug choice procedure.

Authors:  David R Maguire; Charles P France
Journal:  Psychopharmacology (Berl)       Date:  2018-06-03       Impact factor: 4.530

Review 9.  Medical Use of Cannabinoids.

Authors:  Ana Isabel Fraguas-Sánchez; Ana Isabel Torres-Suárez
Journal:  Drugs       Date:  2018-11       Impact factor: 9.546

10.  Cannabinoid modulation of opioid analgesia and subjective drug effects in healthy humans.

Authors:  Shanna Babalonis; Michelle R Lofwall; Paul A Sloan; Paul A Nuzzo; Laura C Fanucchi; Sharon L Walsh
Journal:  Psychopharmacology (Berl)       Date:  2019-06-15       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.